tbuckley/cabot-search huggingface dataset:
PKC412 (Midostaurin) Is Safe and Highly Effective in Systemic Mastocytosis Patients: The Bologna Experience
Authors: Cristina Papayannidis, Mariachiara Abbenante, Sarah Parisi, Stefania Paolini, Ilaria Iacobucci, Federica Frabetti, Emanuela Ottaviani, Anna Ferrari, Viviana Guadagnuolo, Chiara Sartor, Simona Soverini, Caterina De Benedittis, Carmen Baldazzi, Nicoletta Testoni, Michele Baccarani, Giovanni Martinelli
Journal: Blood (2012)
Transforming and Tumorogenic Activity of JAK2 by Fusion to BCR: Molecular Mechanisms of Action of a Novel BCR-JAK2 Tyrosin-Kinase.
Authors: Álvaro Cuesta-Domínguez, Mara Ortega, Cristina Ormazabal, Matilde Santos-Roncero, Marta Galán-Díez, Juan Luis Steegmann, Eva Arranz, María Ángeles Figuera, Jaqueline Sayyah, Peter P. Sayeski, José Luis Vizmanos, Juan A. Bueren, Paula Rio, Elena Fernandez-Ruiz
Journal: Blood (2009)
Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups.
Authors: Lionel Ades, Pau Montesinos, Sylvie Chevret, Edo Vellenga, Emmanuel Raffoux, Chelo Rayon, Joaquim Díaz-Mediavilla, Xavier Thomas, Patrice Chevallier, Concha Rivas, Agnes Guerci, Elena Amutio, Francoise Huguet, Jesus Arias, Norbert Vey, Guillermo Deben, Sandrine Meyer, Andres Novo, Augustin Ferrant, Juan Bergua, Mathieu Resche Rigon, Javier de la Serna, Herve Dombret, Sylvie Castaigne, Pierre Fenaux, Miguel A. Sanz
Journal: Blood (2009)
Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology
Authors: Oliver D. Howes, Rob McCutcheon, Ofer Agid, Andrea de Bartolomeis, Nico J.M. van Beveren, Michael L. Birnbaum, Michael A.P. Bloomfield, Rodrigo A. Bressan, Robert W. Buchanan, William T. Carpenter, David J. Castle, Leslie Citrome, Zafiris J. Daskalakis, Michael Davidson, Richard J. Drake, Serdar Dursun, Bjørn H. Ebdrup, Helio Elkis, Peter Falkai, W. Wolfgang Fleischacker, Ary Gadelha, Fiona Gaughran, Birte Y. Glenthøj, Ariel Graff-Guerrero, Jaime E.C. Hallak, William G. Honer, James Kennedy, Bruce J. Kinon, Stephen M. Lawrie, Jimmy Lee, F. Markus Leweke, James H. MacCabe, Carolyn B. McNabb, Herbert Meltzer, Hans-Jürgen Möller, Shinchiro Nakajima, Christos Pantelis, Tiago Reis Marques, Gary Remington, Susan L. Rossell, Bruce R. Russell, Cynthia O. Siu, Takefumi Suzuki, Iris E. Sommer, David Taylor, Neil Thomas, Alp Üçok, Daniel Umbricht, James T.R. Walters, John Kane, Christoph U. Correll
Journal: American Journal of Psychiatry (2016)

Research and clinical translation in schizophrenia is limited by inconsistent definitions of treatment resistance and response. To address this issue, the authors evaluated current approaches and then developed consensus criteria and guidelines.
Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).
Authors: Richard A. Adams, David Fisher, Susan Farragher, Bharat Jasani, Christopher G. Smith, Michelle D. James, Jeremy Cheadle, Laura L. Nichols, Angela M. Meade, Richard S. Kaplan, Richard H. Wilson, Harpreet Wasan, Tim Maughan
Journal: Journal of Clinical Oncology (2012)

32 Background: Previous data suggests the EGF ligands EREG/AREG may predict outcome of KRAS wt patients (pts) treated with cet in the chemo-refractory setting but this finding has not been previously reported from first line randomised trials. Methods: FFPE samples from primary tumours of pts in Arms A&amp;B of the COIN trial of Ox fluoropyrimidine (Fp) +/- cet were analysed for EGFR IHC, KRAS/NRAS/BRAF mutation and EREG/AREG expression by RT-PCR. Ligand levels were assessed against baseline data, prognostic markers as uni/multivariate analyses and as predictive markers in wild type (wt) and mutant (mt) cohorts and separately by Fp backbone [capecitabine (CapOx) or 5FU (FOLFOX)]. Tests for interaction were performed with EREG/AREG continuous, using Flexible Parametric survival analysis. Results: 952/1630 (57%) of pts were evaluable for all parameters. High EREG/AREG levels were associated with KRAS wt (p&lt;0.005), BRAF wt, absence of MSI and with primary tumour in left colon/rectum, presence of liver metastases, post randomisation radical surgery, high CEA (p&lt;0.05) and ALKP. In the control arm, high EREG/AREG conferred a better prognosis among KRAS wt pts in a multivariate analysis. High EREG predicted for OS benefit from cet. treatment in KRAS wt pts, (n=525, p=0.017) and, separately, in pts treated with FOLFOX (n=310, p=0.021), with greatest effect in the “combined” subgroup (KRAS wt + FOLFOX, n=176, p=0.0042). Conversely a trend towards disbenefit was observed in KRAS wt pts treated with XELOX (n=349, p=0.14). Conclusions: The data suggest a prognostic effect of EREG/AREG in aCRC. The original hypothesis, that KRAS wt patients with high EREG expression have improved outcome with cet, is limited to patients treated with FOLFOX in the first-line setting. This data further suggests that capecitabine in combination with oxaliplatin and cetuximab produces a sub-optimal outcome.
Influence of preoperatively detected circulating tumor cells on the outcome of patients with urothelial carcinoma of the bladder treated with radical cystectomy.
Authors: Michael Rink, Armin Soave, Felix K. Chun, Roland Dahlem, Sarah Minner, Luis A. Kluth, Sascha A. Ahyai, Hans Heinzer, Roman Heuer, Christian Eichelberg, Oliver Engel, Shahrokh F. Shariat, Klaus Pantel, Margit Fisch, Sabine Riethdorf
Journal: Journal of Clinical Oncology (2012)

268 Background: Circulating tumour cells (CTC) are frequently detectable in the peripheral blood of patients with urothelial cancer of the bladder (UCB) prior to radical cystectomy (RC). We hypothesize that CTC can predict advanced stages, nodal status and disease outcome after radical cystectomy and therefore represent an optimal biomarker for treatment decision making and patient counseling. Methods: Blood samples of 120 consecutive, clinically non-metastatic UCB patients scheduled for RC were prospectively investigated for CTC. Preoperatively collected blood samples (7.5 ml) were analysed for CTC using the CellSearch system (Veridex, USA). Uni- and multivariable models evaluated the association of CTC status and number of CTC with clinical and nodal stage and disease outcome. Results: CTC were detectable in 30/120 patients (25%) with an average number of 5.7±18.3 CTC (range:1-100; median:1). Eighteen patients (60.0%) had 1 CTC/7.5mL, 8 patients (26.7%) had 2-5 CTC and 4 patients (13.3%) had &gt;5 CTC, respectively. CTC status was not associated with tumour stage, grade, lymph node metastases or lymphovascular invasion. Moreover, increasing numbers of CTC were not associated with higher stages or increasing numbers of lymph node metastases. However, at a median follow-up of 18 months (range:1-48 months) CTC detection prior to RC was an independent risk factor for disease recurrence (p&lt;0.001, HR=4.9, 95%CI 2.1–11.7) and cancer-related death (p=0.002, HR=4.9, 95%CI 1.7-13.6). Disease recurrence and cancer-related death were not associated with the number of detected CTC. Conclusions: Although CTC can not predict pathological or nodal stage, they are associated with inferior disease outcome. Detection of even 1 CTC/7.5 mL blood in UCB patients prior to RC is an independent predictor for disease recurrence and cancer-related death. These findings are very important for future investigations, as they are in contradiction to theories supporting a cut-off value of 5 or more CTC needed for accurate outcome prediction. Therefore, CTC may represent a feasible biomarker for monitoring response to neoadjuvant and adjuvant chemotherapy.
Cosmetic outcome 1, 2, 3, and 4 years after intraoperative radiotherapy or external beam radiotherapy for early breast cancer: An objective assessment of patients from a randomized controlled trial.
Authors: M. R. Keshtgar, N. R. Williams, T. Corica, C. Saunders, M. Bulsara, D. J. Joseph
Journal: Journal of Clinical Oncology (2011)

94 Background: The randomized controlled TARGIT Trial was designed to determine noninferiority between the novel technique of TARGIT [intra-operative radiotherapy with Intrabeam (Carl Zeiss, Germany)] and conventional external beam radiotherapy (EBRT) in women with early breast cancer. The main outcome objective is risk of local relapse within the treated breast. We report here data from a subprotocol assessing cosmesis in 114 women over 50 years old participating in the TARGIT Trial from one center (Perth, Australia). Methods: Frontal view digital photographs from were assessed, blind to treatment, using specialist software (BCCT.core 2.0, INESC Porto, Portugal) that produces an objective composite score based on symmetry, color, and scar. Data on patient and tumor characteristics were obtained from hospital notes. Statistical analysis was by generalized estimating equations (GEE) on all data, and logistic regression analysis at year 1 only. Results: Photographs were taken at baseline (before surgery) and 1, 2, 3, and 4 years after initial breast-conserving surgery; none of the 114 patients had subsequent breast surgery. Median age at randomization was 62 years (IQR 56 to 68). The composite scores were dichotomized into Excellent and Good (EG), and Fair and Poor (FP). There was a nonsignificant 45% increase in the odds of having an outcome of EG for patients in the TARGIT group relative to the EBRT group (OR=1.45, 95%CI 0.78 – 2.69, p=0.245) after adjusting for tumour size. The results were similar when adjusted for tumor grade and age of the patient. For year 1 there was a statistically significant 2.35 fold increase in the odds of having an outcome of EG for patients in the TARGIT group relative to the EBRT group (OR=2.35, 95%CI 1.02 – 5.45, p=0.047) after adjusting for age of the patient, tumor size, and grade. Conclusions: These results confirm a significantly better cosmetic outcome with TARGIT compared to EBRT in the first year after surgery.
Timeliness of breast tissue pathology reports: Quality thresholds for breast centers.
Authors: C. S. Kaufman, L. D. Shockney, J. Landercasper, B. Rabinowitz, J. B. Askew, D. Wiggins, T. Quality Committee
Journal: Journal of Clinical Oncology (2011)

204 Background: The National Quality Measures for Breast Centers (NQMBC) was started in 2005 to provide quality metrics for breast centers. Each center enters confidential aggregate results to questions regarding the process of breast care. Each data entry can be immediately compared with all other centers. We reviewed data regarding the timeliness of pathology reports after tissue sampling to look for variation among different types of breast centers. Methods: We reviewed the following measures: 1) Time between needle/core biopsy and availability of pathology report; 2) Time between surgical biopsy and availability of pathology report; and 3) Time between initial cancer surgery and availability of pathology report. We looked for variation in results according to structural differences of breast centers. Results: There were 391 center entries reviewing over 21,000 patient encounters between 2005 and 2011. Results included percentiles at 10, 25, 50, 75, and 90 and mean value. Overall, pathology reports for needle biopsy were available much sooner (mean 1.4 days) than any surgical biopsy or excision (2.1, 2.4 days). Results were not altered according to demographic characteristics (type of center, cancer volume, financial structure, size of city and geographic location). Conclusions: The timeliness of pathology reporting of breast specimens is very consistent throughout the participating NQMBC centers, regardless of type and size of breast center. In view of the consistency of those results, a threshold level of care (10 th percentile) may be identified above which all centers should be expected to perform. This minimum level of performance is called the quality threshold. Centers that do not perform above this quality threshold should be ready to explain why their performance falls below this level. Centers who surpass this quality threshold should strive for a quality goal (50 th percentile). We expect that by setting both the quality threshold and the quality goal for each measurement, we will have ongoing encouragement for achievable improvement for each measure.
Symptom Burden In Patients with Chronic Myeloid Leukemia (CML) on Kinase Inhibitor (KI) Therapy.
Authors: Loretta A Williams, Araceli Garcia-Gonzalez, Patricia S Ault, Janet L Williams, Gary M Mobley, Tito R Mendoza, Charles S Cleeland, Jorge E. Cortes
Journal: Blood (2010)
Risk Factors for Vancomycin Resistant Enterococcus (VRE) Infection and Its Influence On Survival After Allogeneic Hematopoietic Progenitor Cell Transplantation (aHPCT)
Authors: Maia Tavadze, Sherif Mossad, Lisa Rybicki, Robin Avery, Melissa Yurch, Brad Pohlman, Hien K. Duong, Robert M Dean, Brian T. Hill, Steven Andresen, Rabi Hanna, Edward A. Copelan, Brian J. Bolwell, Matt Kalaycio, Ronald Sobecks
Journal: Blood (2012)
Targeting the CXCR4-CXCL12 Pathway Using an Anti-CXCR4 IgG1 Antibody (PF-06747143) in Chronic Lymphocytic Leukemia
Authors: Manoj K. Kashyap, Carlos I. Amaya-Chanaga, Deepak Kumar, Michael Y. Choi, Laura Z. Rassenti, Amine Ale-Ali, Shu-Hui Liu, Tod Smeal, Valeria Fantin, Thomas J. Kipps, Flavia Pernasetti, Januario E. Castro
Journal: Blood (2015)
ARHGAP21 Is Overexpressed in Bone Marrow of Acute Leukemia Patients and Interacts with Focal Adhesion Kinase (FAK) in Hematopoietic Cells.
Authors: Fabiola Traina, Sheila M.B. Winnischofer, Luciene Borges, Mariana Lazarini, Carolina L. Bigarella, Fernando F. Costa, Sara T.O. Saad
Journal: Blood (2006)
Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host.
Authors: Andrea Boni, Pawel Muranski, Claudia Wrzesinski, Andrew Kaiser, Chrystal Paulos, Douglas Palmer, Luca Gattinoni, Nicholas P. Restifo
Journal: Blood (2006)
Toll like Receptor 2/6 but Not 1/2 Signaling Promotes Leukemogenesis in a Mouse Model of Myelodysplastic Syndrome
Authors: Sima T Bhatt, Darlene Monlish, Eric J. Duncavage, John Luke Keller, Bilski Rachel, Tanja Le, Matthew J. Walter, Laura G. Schuettpelz
Journal: Blood (2016)
Patients with liver cancer suitable for sorafenib evaluation registry (LIVER) in Poland.
Authors: Krzysztof Krzemieniecki, Krzysztof Simon, Krzysztof Zieniewicz, Pawel Pecilo
Journal: Journal of Clinical Oncology (2012)

194 Background: Due to chronic hepatitis and cirrhosis as main risk factors of HCC – patients in Poland can be treated either by oncologists or by gastroenterologists. As no data exist on HCC patient flow between these specialities, this registry was set up. We also wanted to know the differences in both specialities’ approach to targeted therapies. Methods: Data of patients treated by oncologists (LIVER 2) and gastroenterologists (LIVER 1) were recorded. Descriptive statistical methods and U-Mann-Whitney and Fisher tests were used. Results: 478 patients were included into registry from 2009 until the end of 2010. 70% of patients were male. In 42% cases HCC was caused by HCV and in 24% by HBV. LIVER 2 recorded more patients with unknown HCC aetiology than LIVER 1 (35% vs 15%). The HCC diagnosis was made based on CT scan (80%, ns), US scan (74% in LIVER 1 vs 47% in LIVER 2, p&lt;0,0001) or biopsy (72% LIVER 2 vs 48% LIVER 1, p&lt;0,0001). Patients with advanced stage of HCC according to BCLC scale and poor performance status were more frequently seen by oncologists (LIVER 2), similar prevalence in Child Pugh status was observed in both groups (p&lt;0,05 for all). Registry showed differences in frequency of extrahepatic lesions (10% LIVER 1 42% in LIVER 2, p&lt;0,05). Most common co morbidities were diabetes (32%), liver disorders (39%), hypertension (61%), coronary disease (24%). Median AFP level was 100 ng/ml in LIVER 1 and 219 in LIVER 2 (p=0,057). Registry showed that for gastroenterologists reasons to consider sorafenib as next step in therapy was in 47% cases HCC progression, in 51% good performance status and in 55% sorafenib was found as the only one therapy suitable due to contraindications for other treatments. Oncologists consider sorafenib therapy in 56% cases due to HCC progression and in 72% cases due to good performance status. Among patients considered for targeted therapy, approximately 20% presented Child Pugh B status. Conclusions: This is the first detailed HCC registry in Poland covering the different therapeutic area specialists. Patients with more advanced HCC and worse performance status are more frequently treated by oncologists (p&lt;0,05). The data shows need of early HCC detection interdisciplinary system referring patients to the oncologist.
Identification of Two Src Recruitment Sites in the Juxtamembrane Region of Flt3 with Opposing Effects on Flt3-Ligand-Induced Signaling.
Authors: Lars Ronnstrand, Elke Heiss, Christina Sundberg, Kristina Masson, Malin Pedersen, Jianmin Sun, Susanne Bengtsson
Journal: Blood (2005)
CDC Grand Rounds: Modeling and Public Health Decision-Making
Authors: Leah S. Fischer, Scott Santibanez, Richard J. Hatchett, Daniel B. Jernigan, Lauren Ancel Meyers, Phoebe G. Thorpe, Martin I. Meltzer
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Mathematical models incorporate various data sources and advanced computational techniques to portray real-world disease transmission and translate the basic science of infectious diseases into decision-support tools for public health. Unlike standard epidemiologic methods that rely on complete data, modeling is needed when there are gaps in data. By combining diverse data sources, models can fill gaps when critical decisions must be made using incomplete or limited information. They can be used to assess the effect and feasibility of different scenarios and provide insight into the emergence, spread, and control of disease. During the past decade, models have been used to predict the likelihood and magnitude of infectious disease outbreaks, inform emergency response activities in real time (1), and develop plans and preparedness strategies for future events, the latter of which proved invaluable during outbreaks such as severe acute respiratory syndrome and pandemic influenza (2-6). Ideally, modeling is a multistep process that involves communication between modelers and decision-makers, allowing them to gain a mutual understanding of the problem to be addressed, the type of estimates that can be reliably generated, and the limitations of the data. As models become more detailed and relevant to real-time threats, the importance of modeling in public health decision-making continues to grow.
Conscious content generated by unconscious action-related adjustments
Authors: Farzaneh Pahlavan, Melana Arouss
Journal: Behavioral and Brain Sciences (2016)

Abstract As mentioned in the target article by Morsella et al., the motor program's contents as a whole do not influence each other in the conscious field; however, research shows that some of their generated aspects could be sensitive to the context of the behavior. Such motivational “context-contamination” leads to voluntarily “turn off” of negative states. Taking place out of the conscious field, these adjustments would have critical influence on behavior, such as aggression.
Resolution of a Clinical Dilemma with Whole Genome Sequencing, and Discovery of a New Mechanism for Generating PML-Rara: Insertional Fusion
Authors: John S. Welch, Li Ding, Ken Chen, David E. Larson, Shashikant Kulkarni, Jacqueline E. Payton, John Wallis, Joelle Veizer, Michael D. McLellan, Tammi L. Vickery, Jerry P. Reed, Daniel C Koboldt, Jeffery Klco, John F. DiPersio, Elaine R. Mardis, Timothy J Ley, Richard K. Wilson, Peter Westervelt
Journal: Blood (2010)
<i>Helicobacter pylori</i> and the risk of Barrett's esophagus: A meta-analysis.
Authors: Augustine Salami, Basile M. Njei, Ivo C. Ditah
Journal: Journal of Clinical Oncology (2012)

35 Background: Helicobacter pylori infection (HPI) is well known to play a role in the carcinogenesis of gastric cancer, and has been associated with MALTomas, pancreatic and colon cancer. Barrett’s esophagus (BE) is associated with a 30 fold increase risk of esophageal adenocarcinoma. However, the association of BE with HPI is unclear. The purpose of this study is to summarise all available evidence on the direction and magnitude of the association between HPI and BE. Methods: Two reviewers independently conducted a systematic search on the Cochrane library, MEDLINE and Pub Med databases from 1980 to Jan 2011. Identified articles comparing HPI in BE with controls were manually reviewed for additional references. H.pylori infection had to be confirmed by culture/serology or histology. Adjusted risk estimates were extracted and summarized using fixed-effects model. Inter-extractor discrepancies were resolved by referring to the original article. Publication bias was assessed using the Begg and Egger tests. Analysis was done using STATA version 11. Results: 21 studies (16 case control and 5 cohort studies) were eligible for analysis. These studies involved 12,458 patients. The overall pooled risk ratio for the association between HPI and BE was 0.75 (95% CI- 0.59-0.94). By study design a similar trend was observed only among the case control studies, 0.54 (95% CI 0.33-0.88). Another subgroup analysis excluding the study by Veith (“outlier”) did not change direction of association. There was no evidence of publication bias or heterogeneity among included studies. Conclusions: This study suggests that HPI is not associated with an increase risk of BE, and may actually confer decrease. These findings are consistent with previously published studies. Further data, preferably from prospective studies is needed to better elucidate the association between HPI and BE for more accurate determination.
Efficacy of transcatheter arterial chemoembolization (TACE) in combination with sorafenib for the treatment of unresectable hepatocellular carcinoma in Chinese patients.
Authors: Xudong Qu, Jianhua Wang, Zhiping Yan
Journal: Journal of Clinical Oncology (2012)

279 Background: The purpose of this prospective trial is to evaluate the efficacy and safety of the concurrent use of TACE and sorafenib in a group of patients with unresectable HCC.The treatment outcomes of this group of patients were also compared in a retrospective fashion with a group of HCC patients with similar characteristics of patient and disease in a case controlled setting. Methods: A total of 45 patients (BCLC stage B/C: 16/29) with unresectable HCC were enrolled between June 2008 and Feb 2011 as experimental group and were treated with combination of sorafenib and TACE according to an institutional protocol. To evaluate the efficacy of the combination therapy, a group of 45 HCC patients (n=45, BCLC stage B/C: 17/28) with comparable baseline characteristics who had been treated with TACE alone in our institute were retrospectively selected as control group to compare the treatment outcomes. Median overall survival was compared between the two groups. Adverse events related to sorafenib were assessed according to CTCAE3.0 to observe safety endpoints. The study was approved by the Institutional Ethics Committee at Zhongshan Hospital, Fudan University, China. Results: The median follow-up time for the entire group of patients was 21 months (12.66 - 29.33). The median survival time for the TACE/sorafenib group was 27 months (21.89 - 32.10), and that for TACE alone group was 17 months (8.9 - 25.04) (P&lt;0.05). The most common adverse events associated with sorafenib were hand-foot skin reaction (82.2%), rash (57.94%) and diarrhea (48.91%). Most of the drug-related adverse events were manageable with dose modification, and no CTCAE Grade 4 adverse event was observed. Conclusions: The combination treatment of TACE and sorafenib significantly prolonged median survival in Chinese patients with unresectable HCC, with well tolerated safety profile.